Staidson Biopharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gohibic (vilobelimab) / Staidson Biopharma, InflaRx
NCT05964413: Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

Recruiting
3
90
Europe, US, RoW
vilobelimab, Placebo
InflaRx GmbH
Pyoderma Gangrenosum
02/26
05/26
NCT04449588 / 2020-001671-32: Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

Terminated
2/3
369
Europe, RoW
BDB-001 Injection, Conventional treatment
Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Defengrui Biotechnology Co. Ltd
COVID-19 Pneumonia
03/24
03/24
Beijing_COVID-19: Anti-C5a monoclonal antibody in development for COVID-19 as well as hidradenitis suppurativa

Not yet recruiting
2
0
China
CaCP29 - InflaRx, Staidson Biopharma
InflaRx, Staidson Biopharma, Beijing Defengrei Biotechnology Co, Staidson (Beijing) Pharmaceutical Co., Ltd.
Coronavirus Disease
 
 
2020-000864-42: IFX-1 ALONE OR IN COMBINATION WITH PEMBROLIZUMAB TO TREAT LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA THAT DOES NOT RESPOND TO PD1- OR PD-L1-DIRECTED THERAPY

Not yet recruiting
2
70
Europe
IFX-1, MK-3475, Concentrate for solution for infusion
InflaRx GmbH, InflaRx GmbH
Locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC), Locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC), Diseases [C] - Cancer [C04]
 
 
2020-003273-21: Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA).

Not yet recruiting
2
18
Europe
IFX-1, Concentrate for solution for infusion
InflaRx GmbH, InflaRx GmbH
Pyoderma gangrenosum, Pyoderma gangrenosum, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT05093855: Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed
2
41
RoW
BDB-001 Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hidradenitis Suppurativa
08/23
08/23
KEYNOTE MK3475-PNA93, NCT04812535 / 2020-000864-42: Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Checkmark Initiated Phase II trial of Vilobelimab in combination with Pembrolizumab for cSCC
Mar 2022 - Mar 2022: Initiated Phase II trial of Vilobelimab in combination with Pembrolizumab for cSCC
Terminated
2
30
Europe, US
Vilobelimab, Vilobelimab + pembrolizumab combination therapy, KEYTRUDA®
InflaRx GmbH, Merck Sharp & Dohme LLC
SCC - Squamous Cell Carcinoma of Skin
06/24
06/24
NCT06701682: JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

Recruiting
2
200
US
Cohort A: vilobelimab, Cohort A: placebo
PPD Development, LP, Biomedical Advanced Research and Development Authority, InflaRx GmbH, Edesa Biotech Inc., Genentech, Inc.
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
11/27
02/28
NCT06703073: JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

Recruiting
2
600
US
Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart, Cohort B: placebo, Cohort C: bevacizumab, Cohort C: placebo
PPD Development, LP, Biomedical Advanced Research and Development Authority, InflaRx GmbH, Edesa Biotech Inc., Genentech, Inc.
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
11/27
02/28
NCT05103423: Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed
1/2
50
RoW
BDB-001 Injection, Placebo
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hidradenitis Suppurativa
07/23
07/23
NCT05197842: Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Recruiting
1/2
100
RoW
BDB-001 injection, Cyclophosphamide, Glucocorticoids, Prednisone
Staidson (Beijing) Biopharmaceuticals Co., Ltd
ANCA-associated Vasculitis
03/25
03/25
bemiltenase alfa (STSP-0601) / Staidson Biopharma
NCT06922045: Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

Recruiting
3
32
RoW
STSP-0601 for Injection
Jiangsu BioJeTay Biotechnology Co., Ltd.
Hemophilia
09/26
12/26
NCT05619926: Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Completed
2
32
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Novikang Medical Technology Co., LTD
Hemophilia
08/23
08/23
STSP-0601-04, NCT06289166: Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor

Completed
2
25
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hemophilia
10/24
10/24
NCT05027230: A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Completed
1/2
77
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hemophilia
07/23
07/23
NCT04747964: A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Completed
1
16
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hemophilia
04/21
04/21
STSA-1002 / Staidson Biopharma
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome

Recruiting
1/2
60
RoW
STSA-1002 Injection Placebo, STSA-1002 Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Acute Respiratory Distress Syndrome
08/25
09/26
NCT05166837: The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects

Completed
1
52
RoW
STSA-1002 injection, Placebo
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Healthy
01/23
01/23
NCT05497635: A Study of STSA-1002 in Healthy Subjects

Completed
1
26
RoW
STSA-1002 Injection, Placebo
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Healthy Subject
04/23
04/23
NCT05702983: The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

Completed
1
20
US
STSA-1002 subcutaneous injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Antineutrophil Cytoplasmic Antibody Associated Vasculitis
04/23
04/23
NCT05559125: A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

Terminated
1
50
RoW
STSA-1002 Injection, STSA-1005 Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Healthy Subject
03/24
03/24
STSA-1005 / Staidson Biopharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gohibic (vilobelimab) / Staidson Biopharma, InflaRx
NCT05964413: Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

Recruiting
3
90
Europe, US, RoW
vilobelimab, Placebo
InflaRx GmbH
Pyoderma Gangrenosum
02/26
05/26
NCT04449588 / 2020-001671-32: Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

Terminated
2/3
369
Europe, RoW
BDB-001 Injection, Conventional treatment
Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Defengrui Biotechnology Co. Ltd
COVID-19 Pneumonia
03/24
03/24
Beijing_COVID-19: Anti-C5a monoclonal antibody in development for COVID-19 as well as hidradenitis suppurativa

Not yet recruiting
2
0
China
CaCP29 - InflaRx, Staidson Biopharma
InflaRx, Staidson Biopharma, Beijing Defengrei Biotechnology Co, Staidson (Beijing) Pharmaceutical Co., Ltd.
Coronavirus Disease
 
 
2020-000864-42: IFX-1 ALONE OR IN COMBINATION WITH PEMBROLIZUMAB TO TREAT LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA THAT DOES NOT RESPOND TO PD1- OR PD-L1-DIRECTED THERAPY

Not yet recruiting
2
70
Europe
IFX-1, MK-3475, Concentrate for solution for infusion
InflaRx GmbH, InflaRx GmbH
Locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC), Locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC), Diseases [C] - Cancer [C04]
 
 
2020-003273-21: Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA).

Not yet recruiting
2
18
Europe
IFX-1, Concentrate for solution for infusion
InflaRx GmbH, InflaRx GmbH
Pyoderma gangrenosum, Pyoderma gangrenosum, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT05093855: Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed
2
41
RoW
BDB-001 Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hidradenitis Suppurativa
08/23
08/23
KEYNOTE MK3475-PNA93, NCT04812535 / 2020-000864-42: Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Checkmark Initiated Phase II trial of Vilobelimab in combination with Pembrolizumab for cSCC
Mar 2022 - Mar 2022: Initiated Phase II trial of Vilobelimab in combination with Pembrolizumab for cSCC
Terminated
2
30
Europe, US
Vilobelimab, Vilobelimab + pembrolizumab combination therapy, KEYTRUDA®
InflaRx GmbH, Merck Sharp & Dohme LLC
SCC - Squamous Cell Carcinoma of Skin
06/24
06/24
NCT06701682: JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

Recruiting
2
200
US
Cohort A: vilobelimab, Cohort A: placebo
PPD Development, LP, Biomedical Advanced Research and Development Authority, InflaRx GmbH, Edesa Biotech Inc., Genentech, Inc.
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
11/27
02/28
NCT06703073: JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

Recruiting
2
600
US
Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart, Cohort B: placebo, Cohort C: bevacizumab, Cohort C: placebo
PPD Development, LP, Biomedical Advanced Research and Development Authority, InflaRx GmbH, Edesa Biotech Inc., Genentech, Inc.
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
11/27
02/28
NCT05103423: Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed
1/2
50
RoW
BDB-001 Injection, Placebo
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hidradenitis Suppurativa
07/23
07/23
NCT05197842: Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Recruiting
1/2
100
RoW
BDB-001 injection, Cyclophosphamide, Glucocorticoids, Prednisone
Staidson (Beijing) Biopharmaceuticals Co., Ltd
ANCA-associated Vasculitis
03/25
03/25
bemiltenase alfa (STSP-0601) / Staidson Biopharma
NCT06922045: Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

Recruiting
3
32
RoW
STSP-0601 for Injection
Jiangsu BioJeTay Biotechnology Co., Ltd.
Hemophilia
09/26
12/26
NCT05619926: Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Completed
2
32
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Novikang Medical Technology Co., LTD
Hemophilia
08/23
08/23
STSP-0601-04, NCT06289166: Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor

Completed
2
25
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hemophilia
10/24
10/24
NCT05027230: A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Completed
1/2
77
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hemophilia
07/23
07/23
NCT04747964: A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Completed
1
16
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hemophilia
04/21
04/21
STSA-1002 / Staidson Biopharma
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome

Recruiting
1/2
60
RoW
STSA-1002 Injection Placebo, STSA-1002 Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Acute Respiratory Distress Syndrome
08/25
09/26
NCT05166837: The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects

Completed
1
52
RoW
STSA-1002 injection, Placebo
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Healthy
01/23
01/23
NCT05497635: A Study of STSA-1002 in Healthy Subjects

Completed
1
26
RoW
STSA-1002 Injection, Placebo
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Healthy Subject
04/23
04/23
NCT05702983: The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

Completed
1
20
US
STSA-1002 subcutaneous injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Antineutrophil Cytoplasmic Antibody Associated Vasculitis
04/23
04/23
NCT05559125: A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

Terminated
1
50
RoW
STSA-1002 Injection, STSA-1005 Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Healthy Subject
03/24
03/24
STSA-1005 / Staidson Biopharma
No trials found

Download Options